ME
VIVO

McIlrath & Eck’s Meridian Bioscience Inc VIVO Stock Holding History

McIlrath & Eck’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-570
Closed -$18K – 927
2022
Q3 		$18K Hold
570
– – ﹤0.01% 429
2022
Q2 		$17K Hold
570
– – 0.01% 416
2022
Q1 		$15K Hold
570
– – ﹤0.01% 462
2021
Q4 		$12K Hold
570
– – ﹤0.01% 516
2021
Q3 		$11K Hold
570
– – ﹤0.01% 518
2021
Q2 		$13K Hold
570
– – ﹤0.01% 487
2021
Q1 		$15K Buy
+570
New +$13.6K 0.01% 409

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

McIlrath & Eck's VIVO Position: Q4 2022 in Review

McIlrath & Eck sold out of Meridian Bioscience Inc (VIVO) in Q4 2022, closing a stake of 570 shares — an estimated $18K sold.

McIlrath & Eck first reported a position in VIVO in Q1 2021 and held it in 7 quarters. The position peaked at $18K in Q3 2022. 218 funds tracked by Wall St. Rank hold VIVO as of Q4 2022.

  • McIlrath & Eck reported no remaining Meridian Bioscience Inc position as of Q4 2022 after selling out during the quarter.
  • McIlrath & Eck sold 570 Meridian Bioscience Inc shares in Q4 2022, an estimated $18K.
  • McIlrath & Eck first reported a position in Meridian Bioscience Inc in Q1 2021 and held it in 7 quarters.
  • McIlrath & Eck's Meridian Bioscience Inc position peaked at $18K in Q3 2022.
  • 218 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2022.

Based on McIlrath & Eck's 13F filing for Q4 2022, filed 15 Feb 2023.